ArticleFrontiers in pharmacology2025
Pharmacist-led remote follow-up service for non-metastatic breast cancer patients: a prospective randomised controlled trial of pharmaceutical intervention.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-metastatic breast cancer accounts for 87.8% of breast cancer cases. However, the high risk of drug adverse drug reactions due to multiple combined medications, along with the urgent need for out-of-hospital medication adherence and management, poses substantial challenges. Traditional treatments often fail to meet the full-cycle management needs of patients. Remote pharmaceutical follow-up, as an emerging model, may address these issues. This study aimed to investigate the intervention effect of remote pharmaceutical services via a follow-up app on non-metastatic breast cancer patients. Methods: From May 2023 to March 2025, 178 patients with non-metastatic breast cancer were enrolled and randomly assigned to an intervention group (receiving remote pharmaceutical follow-up via an app) or a control group (receiving only routine treatment), with a 6-month follow-up period. The primary outcome was the incidence of severe adverse drug reactions, while secondary outcomes included medication adherence scores, pharmaceutical knowledge scores, and quality of life assessments. Results: The incidence of severe adverse drug reactions in the intervention group (20.2%) was significantly lower than that in the control group (50.0%, Conclusion: Remote pharmaceutical services delivered via a follow-up app effectively reduce the incidence of severe adverse drug reactions and improve medication knowledge, adherence, and quality of life in non-metastatic breast cancer patients. This model provides a viable new approach for out-of-hospital management and highlights the value of pharmacists in the full-cycle management of oncology care. Future research should further explore preventive strategies for hematological adverse drug reactions and extend the follow-up period to refine the clinical application of this management model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.